Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.

Cancer research - 15 May 2016

Yoshida Akihiro, Lee Eric K, Diehl J Alan

Abstract excerpt

Dysregulation of the p16-cyclin D1-CDK4/6-Rb pathway occurs frequently in melanoma; however, the therapeutic efficacy of CDK4/6 inhibition remains to be critically evaluated. We demonstrate that CDK4/6 inhibition inhibits melanoma progression through induction of senescence. Palbociclib, a specific CDK4/6 inhibitor, rapidly induces cell cycle arrest within 24 hours and continued exposure for 8 days or longer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cyclin-Dependent Kinase 4
Share to Cyclin-Dependent Kinase 6
Share to Immunoenzyme Techniques

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, SCID

Share to Piperazines

Share to Pyridines

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 26988987
DOI: 10.1158/0008-5472.CAN-15-2931
PMCID: PMC4873417

Genes

CDK4
BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.PMID 26988987Read ↗

Palbociclib CDK4/6- and Crizotinib MET/ALK/ROS1-inhibitors Synergize to Enhance Senescence and Immune Recognition in Melanoma Cells Independently of <i>BRAF</i> / <i>NRAS</i> StatusSemantic proximity Read ↗

Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor GrowthSemantic proximity Read ↗

The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in MelanomaSemantic proximity Read ↗

Aurora B Is Regulated by the Mitogen-activated Protein Kinase/Extracellular Signal-regulated Kinase (MAPK/ERK) Signaling Pathway and Is a Valuable Potential Target in Melanoma CellsSemantic proximity Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Characterization of Vemurafenib-Resistant Melanoma Cell Lines Reveals Novel Hallmarks of Targeted Therapy ResistanceSemantic proximity Read ↗

Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.Semantic proximity Read ↗

p16INK4a-induced senescence is disabled by melanoma-associated mutations.Semantic proximity Read ↗

CDK4/6 inhibitor: from quiescence to senescenceSemantic proximity Read ↗

Applications and mechanisms of the cyclin-dependent kinase 4/6 inhibitor, PD-0332991, in solid tumorsSemantic proximity Read ↗

MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.